E-ISSN 2149-2530
Review
Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small-Cell Lung Cancer
1 Department of Medical Oncology, University of Health Science Kanuni Training and Research Hospital, Trabzon, Turkey  
2 Department of Medical Oncology, Dokuz Eylül University School of Medicine, İzmir, Turkey  
turkthoracj 2017; 18: 66-71
DOI: 10.5152/TurkThoracJ.2017.16042
This article was viewed 277 times, downloaded 203 times

Key Words: Epidermal growth factor receptor, tyrosine kinase inhibitors, resistance, non-small-cell lung cancer
Abstract

Systemic treatment is the basic treatment approach to advanced-stage non-small-cell lung cancer (NSCLC), and chemotherapy and targeted treatments are commonly employed in these patients. Recently, positive results achieved with immunotherapy have led to a growing number of treatment options and prolonged survival time. Today, specific tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib, and afatinib, which target the epidermal growth factor receptor (EGFR), and the TKI crizotinib, which targets anaplastic lymphoma kinase gene rearrangement, have become the standard treatment among targeted therapies for patients with sensitive molecular anomalies. However, resistance develops against all these agents after a while. Numerous genetic mutations, T790M+ in particular, have been identified as resistance mechanisms against EGFR-TKIs, and researchers are developing specific inhibitors against them. Among those inhibitors, third-generation EGFR-TKIs such as osimertinib and rociletinib have gained prominence due to their high level of effectiveness and low toxicity profile. Besides, systemic chemotherapy and immunotherapy are proper alternatives. A second biopsy during the progression stage and better clarification of the mechanisms causing secondary resistance will enable more successful treatments in the future. 

 

Cite this article as: Kazaz SN, Öztop I. Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small-Cell Lung Cancer. Turk Thorac J 2017;18:66-71.

Key Words
Authors
All
Author's Corner
Survey
AVES | Copyright © 2017 Turkish Thoracic Society Latest Update: 19.06.2017